Long-term vs Short-term Therapy With Vitamin K Antagonists for Symptomatic Venous Thromboembolism.
Where this comes from
- Record sourced from PubMed, PMID 26151268.
- Also identified by DOI 10.1001/jama.2015.2693.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
CLINICAL QUESTION: Is long-term (≥3 months) vs short-term therapy with vitamin K antagonists (VKAs) associated with differences in the incidence of recurrent venous thromboembolism (VTE), major bleeding, and mortality in patients with symptomatic VTE? BOTTOM LINE: Long-term treatment with VKAs is associated with a reduced risk for recurrent VTE and an increased risk for major bleeding compared with short-term treatment in patients with VTE, but is not associated with differences in mortality.